Meropenem Plasma Concentration Measurements at the Pediatric Medical Ward, Oslo University Hospital, Rikshospitalet

University of Oslo (UIO)

Status: Completed

Conditions: Bacterial Infection

Study type: Observational

Funder types: Other

Identifiers

NCT01289249

2010/3023-1

Details and patient eligibility

About

The object of the study is to investigate whether all included patients receive treatment that is effective against all bacteria that are defined as sensitive to meropenem with the current treatment regimen. Will the investigators findings motivate routine monitoring of plasma concentrations in children receiving meropenem? Up to 50 patients will be included in the study, and all participants are children.

Enrollment: 10 patients

Sex: All

Ages: 3 months to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Children aged from 3 months to 18 years that receive treatment with meropenem. Inclusion is independent of how long the patient has been receiving treatment. Children receiving other treatment (except hemodialysis)/other medications can be included.

Exclusion criteria

• Children less than three months of age. Patients receiving hemodialysis. Lack of consent.

Trial design

10 participants in 1 patient group

Children receiving meropenem

Description:

Children aged from 3 months to 18 years that receive treatment with meropenem.